Table 2.
Change in outcomes between baseline and 6 months in Canadian cohort of HOPE 4
| Outcome | Baseline (n = 56) | 6 months (n = 46) | P∗ |
|---|---|---|---|
| FRS 10-year risk estimate, mean (SD) | 30.6 (18.1) | 24.7 (17.0) | < 0 .01 |
| Current smoker† | 8 (14.8) | 5 (10.9) | — |
| Physically active | 25 (46.3) | 28 (60.9) | 0.11 |
| Use of BP-lowering medications | 37 (68.5) | 35 (76.1) | 0.10 |
| Use of one BP-lowering medication | 17 (45.9) | 11 (31.4) | 0.01 |
| Use of ≥ 2 BP-lowering medications | 20 (54.5) | 24 (68.6) | 0.01 |
| SBP, mm Hg, mean (SD) | 153.1 (12.1) | 136.7 (15.7) | < 0.01 |
| Controlled SBP, < 140 mm Hg | 3 (5.6) | 26 (56.5) | < 0.01 |
| Use of statins | 22 (40.7) | 24 (52.2) | 0.01 |
| Total cholesterol, mmol/L, mean (SD) | 4.8 (1.3) | 4.7 (1.1) | 0.10 |
| LDL, mmol/L, mean (SD) | 2.7 (1.1) | 2.7 (0.9) | 0.15 |
| HDL, (mmol/L), mean (SD) | 1.4 (0.5) | 1.4 (0.5) | 0.15 |
| Triglyceride, mmol/L, mean (SD) | 1.6 (0.7) | 1.6 (0.7) | 0.20 |
Values are n (%), unless otherwise indicated.
BP, blood pressure; FRS, Framingham risk score; HDL, high-density lipoprotein; HOPE, Heart Outcomes Prevention and Evaluation Canada pilot study; LDL. low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.
∗
Based on paired subjects only, who had both baseline and 6 months using paired t-test for continuous measures and McNemar's test for categorical measures.
†
There is no change in smoking status among 46 participants who had both baseline and 6-month follow-up measures. As a result, P is not estimable for this exposure.